Concepedia

Lev Demidov

LD

Statistics

Publications

68

Citations

15.7K

H-Index

36

Active since

1992

Affiliations

Russian Cancer Research Center NN Blokhin(Current)

The Maria Sklodowska-Curie National Research Institute of Oncology

University Hospital of Zurich

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

University Hospital Heidelberg

Lev Demidov is an author at Russian Cancer Research Center NN Blokhin specializing in oncology, medicine, and melanoma pharmacotherapy.

ORCID

Publications per year

1992–2023

68

Publications

68

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations

, , +11

Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · New England Journal of Medicine · 2012 · 2.1K citations · Full text

, , +17

Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma

James Larkin, Paolo A. Ascierto, Brigitte Dréno et al. · New England Journal of Medicine · 2014 · 2K citations · Full text

, , +16

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

Keith T. Flaherty, Caroline Robert, Peter Hersey et al. · Zurich Open Repository and Archive (University of Zurich) · 2012 · 1.3K citations

, , +15

Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno et al. · The Lancet Oncology · 2016 · 1K citations

, , +11

1–5 of 68